FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053946373> ?p ?o ?g. }

• W2053946373 endingPage "558" @default.
• W2053946373 startingPage "547" @default.
• W2053946373 abstract "Japanese Journal of Cancer ResearchVolume 83, Issue 6 p. 547-558 Open Access Basic Design Considerations for Clinical Trials in Oncology Steven Piantadosi, Steven Piantadosi Oncology Biostatistics, Johns Hopkins Oncology Center, 550 North Broadway, Suite 1103, Baltimore, Maryland 21205, USASearch for more papers by this authorNagahiro Saijo, Nagahiro Saijo Pharmacology Division and Medical Oncology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 170, JapanSearch for more papers by this authorTomohide Tamura, Tomohide Tamura Pharmacology Division and Medical Oncology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 170, JapanSearch for more papers by this author Steven Piantadosi, Steven Piantadosi Oncology Biostatistics, Johns Hopkins Oncology Center, 550 North Broadway, Suite 1103, Baltimore, Maryland 21205, USASearch for more papers by this authorNagahiro Saijo, Nagahiro Saijo Pharmacology Division and Medical Oncology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 170, JapanSearch for more papers by this authorTomohide Tamura, Tomohide Tamura Pharmacology Division and Medical Oncology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 170, JapanSearch for more papers by this author First published: June 1992 https://doi.org/10.1111/j.1349-7006.1992.tb00124.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 ) B. L. Leventhal and S. Piantadosi ( ed. ). Issues in clinical research . Sem. Oncol , 15 ( 1988 ). 2 ) Piantadosi , S. Principles of clinical trial design . Sem. Oncol , 15 , 423 – 433 ( 1988 ). 3 ) Meinert , C. L. “ Clinical Trials ” ( 1986 ). Oxford University Press , Oxford . 4 ) Silverman , W. A. “ Human Experimentation: A Guided Step into the Unknown ” ( 1985 ). Oxford University Press , Oxford . 5 ) Armitage , P. The design of clinical trials . Aust. J. Stat. , 21 , 266 – 281 ( 1979 ). 6 ) Louis , T. A. , Mosteller , F. and McPeek , B. Timely topics in statistical methods for clinical trials . Annu. Rev. Biophys. Bioeng. , 11 , 81 – 104 ( 1982 ). 7 ) Lewis , J. A. Clinical trials: statistical developments of practical benefit to the pharmaceutical industry (with discussion) . J. R. Stat. Soc. A , 146 , 362 – 393 ( 1983 ). 8 ) Peto , R. , Pike , M. C. , Armitage , P. , Breslow , N. E. , Cox , D. R. , Howard , S. V. , Mantel , N. , McPherson , K. , Peto , J. and Smith , P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design . Br. J. Cancer , 34 , 585 – 612 ( 1976 ). 9 ) Peto , R. , Pike , M. C. , Armitage , P. , Breslow , N. E. , Cox , D. R. , Howard , S. V. , Mantel , N. , McPherson , K. , Peto , J. and Smith , P. G. Design and analysis of randomized clinical trials requiring prolonged observations of each patient: II. Analysis and examples . Br. J. Cancer , 35 , 1 – 39 ( 1977 ). 10 ) Shapiro , S. H. and Louis , T. A. “ Clinical Trials: Issues and Approaches ” ( 1983 ). Marcel Dekker , New York . 11 ) Pocock , S. J. “ Clinical Trials: A Practical Approach ” ( 1983 ). John Wiley & Sons , New York . 12 ) M. E. Buyse , M. J. Staquet and R. J. Sylvester ( ed. ). “Cancer Clinical Trials. Methods and Practice ” ( 1984 ). Oxford University Press , Oxford . 13 ) Leventhal , B. G. and Wittes , R. E. “ Research Methods in Clinical Oncology ” ( 1988 ). Raven Press , New York . 14 ) Byar , D. P. , Simon , R. M. , Friedewald , W. T. , Schlesselman , J. J. , DeMets , D. L. , Ellenberg , J. H. , Gail , M. H. and Ware , J. H. Randomized clinical trials: perspectives on some recent ideas . N. Engl. J. Med. , 295 , 74 – 80 ( 1976 ). 15 ) Freidman , L. M. , Furberg , C. D. and DeMets , D. L. “ Fundamentals of Clinical Trials ” ( 1981 ). John Wright , Boston . 16 ) Office of Technology Assessment, U.S. Congress . The Impact of Randomized Clinical Trials on Health Policy and Medical Practice: Background Paper . OTA-BP-H-22 ( 1983 ). US Government Printing Office , Washington , D.C . 17 ) Bull , J. P. The historical development of clinical therapeutic trials . J. Chronic Dis. , 10 , 218 – 248 ( 1959 ). 18 ) “Dorland's Medical Dictionary, 27th Edition ” ( 1988 ). W. B. Saunders Co. , Philadelphia . 19 ) “Stedman's Medical Dictionary, 25th Edition ” ( 1990 ). Williams and Wilkins , Baltimore . 20 ) Sommer , A. and Zeger , S. L. On estimating efficacy from clinical trials . Stat. Med. , 10 , 45 – 52 ( 1991 ). 21 ) Newcombe , R. G. Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur . Stat. Med. , 7 , 1179 – 1186 ( 1988 ). 22 ) Gail , M. H. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials . Cancer Treat. Rep. , 69 , 1107 – 1112 ( 1985 ). 23 ) Byar , D. P. Why data bases should not replace randomized clinical trials . Biometrics , 36 , 337 – 342 ( 1980 ). 24 ) Freiman , J. A. , Chalmers , T. C. , Smith , H. , Jr. and Kuebler , R. R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial. Survey of 71 “negative” trials . N. Engl. J. Med. , 299 , 690 – 694 ( 1976 ). 25 ) Sackett , D. L. Bias in analytic research . J. Chronic Dis. , 32 , 51 – 63 ( 1979 ). 26 ) Fleiss , J. L. , Tytun , A. and Ury , H. K. A simple approximation for calculating sample size for comparing independent proportions . Biometrics , 36 , 343 – 346 ( 1980 ). 27 ) Donner , A. Approaches to sample size estimation in the design of clinical trials — a review . Stat. Med. , 3 , 199 – 214 ( 1984 ). 28 ) Piantadosi , S. “ Clinical Trials Design Program ” ( 1990 ). BIOSOFT , Cambridge . 29 ) Goldstein , R. Power and sample size via MS/PC-DOS computers . Am. Stat. , 43 , 253 – 260 ( 1989 ). 30 ) Sasaki , Y. , Totani , T. , Shinkai , T. , Eguchi , K. , Tamura , T. , Ohe , Y. , Nakagawa , K. and Saijo , N. A phase I study of cis-diammine (glycolato) platinum (II) (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion: pharmacokinetic and pharmacodynamic analysis . Cancer Res. , 51 , 1472 – 1477 ( 1991 ). 31 ) Von Hoff , D. D. , Kuhn , J. and Clark , G. M. Design, and conduct of phase I trials . In “ Cancer Clinical Trials: Methods and Practice ,” ed. M. E. Buyse , M. J. Staquet and R. J. Sylvester , pp. 210 – 222 ( 1984 ). Oxford Univ. Press , Oxford . 32 ) Carter , S. K. Clinical trials in cancer chemotherapy . Cancer , 40 , 544 – 557 ( 1977 ). 33 ) Muggia , F. M. , Rosenzweig , M. , Staquet , M. J. and McGuire , W. P. , Jr. Methodology of phase II clinical trials in cancer . Recent Results Cancer Res. , 53 – 60 ( 1980 ). 34 ) Herson , J. Statistical aspects in the design and analysis of phase II clinical trials . In “ Cancer Clinical Trials: Methods and Practice ,” ed. M. E. Buyse , M. J. Staquet and R. J. Sylvester , 239 – 260 ( 1984 ). Oxford Univ. Press , Oxford . 35 ) Fukuda , M. , Shinkai , T. , Eguchi , K. , Sasaki , Y. , Tamura , T. , Ohe , Y. , Kojima , A. , Oshita , F. , Hara , K. and Saijo , N. Phase II study of (glycolate-O, O′) diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer . Cancer Chemother. Pharmacol. , 26 , 393 – 396 ( 1990 ). 36 ) Ohe , Y. , Shinkai , T. , Eguchi , K. , Sasaki , Y. , Tamura , T. , Nakagawa , K. , Kojima , A. , Yamada , K. , Oshita , F. , Miya , T. and Saijo , N. Negative phase II study of 5-fluorouracil with high-dose lecovorin in non-small cell lung cancer . Jpn. J. Clin. Oncol. , 20 , 364 – 368 ( 1990 ). 37 ) Piantadosi , S. and Dalesio , O. The randomized phase II clinical trial . Eur. Cancer News , 1 , 3 – 4 ( 1988 ). 38 ) Simon , R. , Wittes , R. E. and Ellenberg , S. Randomized phase II clinical trials . Cancer Treat. Rep. , 69 , 1375 – 1381 ( 1985 ). 39 ) Anscombe , F. J. Sequential medical trials . J. Am. Stat. Assoc. , 58 , 365 – 383 ( 1963 ). 40 ) Armitage , P. , McPherson , C. K. and Rowe , B. C. Repeated significance tests on accumulating data . J. R. Stat. Soc. A , 132 , 235 – 244 ( 1969 ). 41 ) Wald , A. “ Sequential Analysis ” ( 1947 ). John Wiley & Sons , New York . 42 ) Pocock , S. J. Group sequential methods in the design and analysis of clinical trials . Biometrika , 64 , 191 – 199 ( 1977 ). 43 ) O'Brien , P. C. and Fleming , T. R. A multiple testing procedure for clinical trials . Biometrics , 35 , 549 – 556 ( 1979 ). 44 ) Hughes , M. D. and Pocock , S. J. Stopping rules and estimation problems in clinical trials . Stat. Med. , 7 , 1231 – 1242 ( 1988 ). 45 ) Chang , M. N. , Wieand , H. S. and Chang , V. T. The bias of the sample proportion following a group sequential phase II clinical trial . Stat. Med. , 8 , 563 – 570 ( 1989 ). 46 ) Whitehead , J. Designing phase II studies in the context of a programme of clinical research . Biometrics , 41 , 373 – 383 ( 1985 ). 47 ) Whitehead , J. Sample sizes for phase II and phase III clinical trials: an integrated approach . Stat. Med. , 5 , 459 – 464 ( 1986 ). 48 ) Thall , P. F. , Simon , R. and Ellenberg , S. S. Optimal two stage designs for clinical trials with binary response . Stat. Med. , 7 , 571 – 579 ( 1988 ). 49 ) Weiand , S. and Therneau , T. A two stage design for randomized trials with binary outcomes . Controlled Clin, Trials , 8 , 20 – 28 ( 1987 ). 50 ) Ellenberg , S. S. and Eisenberger , M. A. An efficient design for phase III studies of combination chemotherapies . Cancer Treat. Rep. , 69 , 1147 – 1152 ( 1985 ). 51 ) Herson , J. and Carter , S. K. Calibrated phase II clinical trials in oncology . Stat. Med. , 5 , 441 – 447 ( 1986 ). 52 ) Armitage , P. The search for optimality in clinical trials . Int. Stat. Rev. , 53 , 15 – 24 ( 1985 ). 53 ) Peto , R. Discussion of ‘On the allocation of treatments in sequential medical trials’ by J. A. Bather and ‘The search for optimality in clinical trials’ by P. Armitage . Int. Stat. Rev. , 53 , 31 – 34 ( 1985 ). 54 ) Chalmers , T. C. The control of bias in clinical trials . In “ Clinical Trials: Issues and Approaches ,” ed. S. H. Shapiro and T. A. Louis , pp. 115 – 127 ( 1983 ). Marcel Dekker , New York . 55 ) Green , S. B. Randomized clinical trials: design and analysis . Sem. Oncol. , 8 , 417 – 423 ( 1981 ). 56 ) Gehan , E. A. and Freireich , E. J. Non-randomized controls in cancer clinical trials . N. Engl. J. Med. , 290 , 198 – 203 ( 1974 ). 57 ) Green , S. B. and Byar , D. P. The effect of stratified randomization on size and power of statistical tests in clinical trials . J. Chronic Dis. , 31 , 445 – 454 ( 1978 ). 58 ) Palta , M. Investigating maximum power losses in survival studies with nonstratified randomization . Biometrics , 41 , 497 – 504 ( 1985 ). 59 ) Bailar , J. C. Patient assignment algorithms: an overview . In “ Proceedings of the 9th International Biometric Conference. Vol. I ,” pp. 189 – 206 ( 1976 ). The Biometric Society , Raleigh , N.C . 60 ) Simon , R. Adaptive treatment assignment methods and clinical trials . Biometrics , 33 , 743 – 749 ( 1977 ). 61 ) Kalish , L. A. and Begg , C. B. Treatment allocation methods in clinical trials: a review . Stat. Med. , 4 , 129 – 144 ( 1985 ). 62 ) Efron , B. Forcing a sequential experiment to be balanced . Biometrika , 58 , 403 – 417 ( 1971 ). 63 ) Pocock , S. J. and Simon , R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial . Biometrics , 31 , 103 – 115 ( 1975 ). 64 ) Freedman , L. A. and White , S. J. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial . Biometrics , 32 , 691 – 694 ( 1976 ). 65 ) Begg , CD. and Iglewicz , B. A. A treatment allocation procedure for sequential clinical trials . Biometrics , 36 , 81 – 90 ( 1980 ). 66 ) Simon , R. Restricted randomization designs in clinical trials . Biometrics , 35 , 503 – 512 ( 1979 ). 67 ) Senn , S. J. Covariate imbalance and random allocation in clinical trials . Stat. Med. , 8 , 467 – 475 ( 1989 ). 68 ) O'Fallon , J. R. Policies for interim analysis and interim reporting of results . Cancer Treat. Rep. , 69 , 1101 – 1106 ( 1985 ). 69 ) Cornfield , J. Recent methodologic contributions to clinical trials . Am. J. Epidemiol , 104 , 408 – 421 ( 1976 ). 70 ) Berry , D. A. Interim analyses in clinical trials: classical versus Bayesian approaches . Stat. Med. , 4 , 521 – 526 ( 1985 ). 71 ) Berry , D. A. Interim analyses in clinical trials: the role of the likelihood principle . Am. Stat. , 41 , 117 – 122 ( 1987 ). 72 ) Gail , M. H. Monitoring and stopping clinical trials . In “ Statistics in Medical Research ,” ed. V. Mike and K. E. Stanley , pp. 455 – 484 ( 1982 ). Wiley , New York . 73 ) DeMets , D. L. Practical aspects in data monitoring: a brief review . Stat. Med. , 6 , 753 – 760 ( 1987 ). 74 ) Lan , K. K. G. , Simon , R. and Halperin , M. Stochastically curtailed tests in long-term clinical trials . Comm. Stat. , 1 , 207 – 219 ( 1982 ). 75 ) Shinkai , T. , Eguchi , K. , Sasaki , Y. , Tamura , T. , Ohe , Y. , Kojima , A. , Oshita , F. and Saijo , N. A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer . Eur. J. Cancer , 27 , 571 – 575 ( 1991 ). 76 ) Brown , B. W. , Jr. Statistical controversies in the design of clinical trials . Controlled Clin. Trials , 1 , 13 – 27 ( 1980 ). 77 ) Senn , S. J. Cross-over trials, carry-over effects and the art of self-delusion (letter) . Stat. Med. , 7 , 1099 – 1101 ( 1988 ). 78 ) U.S. Food and Drug Administration . “ General Considerations for the Clinical Evaluation of Drugs ,” Pub No. HEW (FDA) 77 – 3040 ( 1977 ). 79 ) Byar , D. P. and Piantadosi , S. Factorial designs for randomized clinical trials . Cancer Treat. Rep. , 69 , 1055 – 1063 ( 1985 ). 80 ) Hennekens , C. H. and Eberlein , K. A. for the Physician's Health Study Research Group. A randomized trial of aspirin and beta-carotene among U.S. physicians . Prev. Med. , 14 , 165 – 168 ( 1985 ). 81 ) Stampfer , M. J. , Burning , J. G. , Willet , W. , Rosner , B. , Eberlein , K. and Hennekens , C. H. The 2×2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians . Stat. Med. , 4 , 111 – 116 ( 1985 ). 82 ) Physicians' Health Study Research Group . Preliminary report: findings from the aspirin component of the ongoing physician's health study . N. Engl. J. Med. , 318 , 262 – 264 ( 1988 ). 83 ) Blot , W. J. and Li , J. Y. Some considerations in the design of a nutrition intervention trial in Linxian, People's Republic of China . Natl. Cancer Inst. Monogr. , 69 ( 1985 ). 84 ) Hennekens , C. H. Issues in the design and conduct of clinical trials . J. Natl. Cancer Inst. , 73 , 1473 – 1479 ( 1984 ). 85 ) Kornitzer , M. , DeBacker , G. , Dramaix , M. , Kittel , F. , Thilly , C. , Graffar , M. and Vuylsteek , K. Belgian heart disease prevention project: incidence and mortality results . Lancet , i , 1066 – 1070 ( 1983 ). 86 ) Donner , A. , Birkett , N. and Buck , C. Randomization by cluster . Am. J. Epidemiol. , 114 , 906 – 914 ( 1981 ). 87 ) Zelen , M. Play-the-winner rule and the controlled clinical trial . J. Am. Stat. Assoc. , 64 , 131 – 146 ( 1969 ). 88 ) Robbins , H. Some aspects of sequential design of experiments . Bull. Am. Math. Soc. 58 , 527 – 535 ( 1972 ). 89 ) Taves , D. R. A new method of assigning patients to treatment and control groups . Clin. Pharmacol. Ther. , 15 , 443 – 453 ( 1974 ). 90 ) Brittain , E. and Schlesselman , J. J. Optimal allocation for the comparison of proportions . Biometrics , 38 , 1003 – 1009 ( 1982 ). 91 ) Sposto , R. and Krailo , M. D. Use of unequal allocation in survival trials . Stat. Med. , 6 , 119 – 125 ( 1987 ). 92 ) Schafer , A. The ethics of the randomized clinical trial . N. Engl. J. Med. , 307 , 719 – 724 ( 1977 ). 93 ) Burkhardt , R. and Kienle , G. Basic problems in controlled trials . J. Med. Ethics , 9 , 80 – 84 ( 1983 ). 94 ) Vere , D. W. Problems in controlled trials — a critical response . J. Med. Ethics , 9 , 85 – 89 ( 1983 ). 95 ) Fukuoka , M. , Furuse , K. , Saijo , N. , Yutaka , N. , Ikegami , H. , Tamura , T. , Shimoyama , M. and Suemasu , K. Randomized trial of cyclophosphamide, doxorubicin and vincristine (CAV) versus cisplatin and etoposide (PE) versus alternation of CAV and PE in small cell lung cancer . J. Natl. Cancer Inst. , 83 , 855 – 861 ( 1991 ). 96 ) Machin , D. , Staquet , M. J. and Sylvester , R. J. Advantages and defects of single-center and multicenter clinical trials . In “ Controversies in Cancer ,” ed. H. J. Tagnon and M. J. Staquet , pp. 7 – 22 ( 1979 ). Masson Publishing , New York . 97 ) Weiss , D. G. , Williford , W. O. , Collins , J. F. and Bingham , S. F. Planning multicenter clinical trials: a biostatistician's perspective . Controlled Clin. Trials , 4 , 53 – 64 ( 1983 ). Citing Literature Volume83, Issue6June 1992Pages 547-558 ReferencesRelatedInformation" @default.
• W2053946373 created "2016-06-24" @default.
• W2053946373 creator A5050855780 @default.
• W2053946373 creator A5058549884 @default.
• W2053946373 creator A5087391729 @default.
• W2053946373 date "1992-06-01" @default.
• W2053946373 modified "2023-09-30" @default.
• W2053946373 title "Basic Design Considerations for Clinical Trials in Oncology" @default.
• W2053946373 cites W128405409 @default.
• W2053946373 cites W1480884888 @default.
• W2053946373 cites W1554801388 @default.
• W2053946373 cites W194711665 @default.
• W2053946373 cites W1956172535 @default.
• W2053946373 cites W1970046651 @default.
• W2053946373 cites W1973574532 @default.
• W2053946373 cites W1976668846 @default.
• W2053946373 cites W1978049560 @default.
• W2053946373 cites W1986376095 @default.
• W2053946373 cites W1990455158 @default.
• W2053946373 cites W1998498767 @default.
• W2053946373 cites W2000366267 @default.
• W2053946373 cites W2001682550 @default.
• W2053946373 cites W2006712493 @default.
• W2053946373 cites W2007296443 @default.
• W2053946373 cites W2007316542 @default.
• W2053946373 cites W2009200425 @default.
• W2053946373 cites W2009815693 @default.
• W2053946373 cites W2012332282 @default.
• W2053946373 cites W2013256551 @default.
• W2053946373 cites W2013372815 @default.
• W2053946373 cites W2014083181 @default.
• W2053946373 cites W2023747410 @default.
• W2053946373 cites W2027576839 @default.
• W2053946373 cites W2030500137 @default.
• W2053946373 cites W2030894970 @default.
• W2053946373 cites W2038252730 @default.
• W2053946373 cites W2043458654 @default.
• W2053946373 cites W2053537247 @default.
• W2053946373 cites W2053915257 @default.
• W2053946373 cites W2055670070 @default.
• W2053946373 cites W2058078699 @default.
• W2053946373 cites W2059337943 @default.
• W2053946373 cites W2059707463 @default.
• W2053946373 cites W2067957641 @default.
• W2053946373 cites W2069594609 @default.
• W2053946373 cites W2070799779 @default.
• W2053946373 cites W2075917870 @default.
• W2053946373 cites W2085054454 @default.
• W2053946373 cites W2086407709 @default.
• W2053946373 cites W2095103739 @default.
• W2053946373 cites W2097597328 @default.
• W2053946373 cites W2099516384 @default.
• W2053946373 cites W2106080096 @default.
• W2053946373 cites W2118533989 @default.
• W2053946373 cites W2121957147 @default.
• W2053946373 cites W2127151679 @default.
• W2053946373 cites W2137411170 @default.
• W2053946373 cites W2141010206 @default.
• W2053946373 cites W2145538152 @default.
• W2053946373 cites W2150379801 @default.
• W2053946373 cites W2158152024 @default.
• W2053946373 cites W2158174150 @default.
• W2053946373 cites W2165563020 @default.
• W2053946373 cites W2320991959 @default.
• W2053946373 cites W2324629379 @default.
• W2053946373 cites W2327587665 @default.
• W2053946373 cites W2395155383 @default.
• W2053946373 cites W2401795134 @default.
• W2053946373 cites W2409366709 @default.
• W2053946373 cites W2411853833 @default.
• W2053946373 cites W2417914947 @default.
• W2053946373 cites W2462244116 @default.
• W2053946373 cites W2467022164 @default.
• W2053946373 cites W2616762518 @default.
• W2053946373 cites W2796376063 @default.
• W2053946373 cites W3023537991 @default.
• W2053946373 cites W4239011888 @default.
• W2053946373 cites W4242263299 @default.
• W2053946373 cites W4245417765 @default.
• W2053946373 cites W4296473084 @default.
• W2053946373 cites W4300667758 @default.
• W2053946373 cites W64094104 @default.
• W2053946373 cites W77437304 @default.
• W2053946373 cites W23616279 @default.
• W2053946373 doi "https://doi.org/10.1111/j.1349-7006.1992.tb00124.x" @default.
• W2053946373 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5918883" @default.
• W2053946373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1644658" @default.
• W2053946373 hasPublicationYear "1992" @default.
• W2053946373 type Work @default.
• W2053946373 sameAs 2053946373 @default.
• W2053946373 citedByCount "5" @default.
• W2053946373 countsByYear W20539463732016 @default.
• W2053946373 crossrefType "journal-article" @default.
• W2053946373 hasAuthorship W2053946373A5050855780 @default.
• W2053946373 hasAuthorship W2053946373A5058549884 @default.
• W2053946373 hasAuthorship W2053946373A5087391729 @default.
• W2053946373 hasBestOaLocation W20539463731 @default.
• W2053946373 hasConcept C121608353 @default.

• next